Companies
Zoetis
Cytopoint, Apoquel, Vaccines — Recombinant mAbs, viral vectors.
- Country
- United States
cGMP
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
| livestock-aqua | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpausda-aphisefsamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | $9.5 billion (2025) | s203.q4cdn.com · zoetis.com |
| Headcount | approximately 14,500 employees worldwide | s203.q4cdn.com · sec.gov · zoetis.com |
| Production site | 21 to 23 manufacturing sites globally, including sites in the U.S. (Kalamazoo, Lincoln, Durham, Buellton, Union City, Atlanta), Ireland, Belgium, Spain, Italy, Brazil, Australia, New Zealand, and China | s203.q4cdn.com · zoetis.com |
| Capacity | Zoetis has expanded capacity for monoclonal antibodies (mAbs) at its Tullamore, Ireland site and is investing $590 million in a new mAb and vaccine facility in Georgia, U.S. | news.zoetis.com |
| Regulatory approval | Key products like Apoquel, Cytopoint, and various recombinant vector vaccines (e.g., Poulvac Procerta line) have received regulatory approvals from bodies such as the FDA (U.S.) and USDA (U.S.), as well as international authorities like the EMA and others for various indications and geographic markets | investor.zoetis.com · keypedia.com · sec.gov · vmd.defra.gov.uk · zoetis.com |
| Certification | Zoetis facilities maintain global regulatory compliance, including Good Manufacturing Practice (GMP) certifications from authorities such as the VMD (UK) and FDA (U.S.) for pharmaceuticals and biologics production | vmd.defra.gov.uk · zoetis.com |
Independent sources: keypedia.com · s203.q4cdn.com · sec.gov · vmd.defra.gov.uk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| One Health — zoonosis & AMR monitoring as a service | diagnostics-medtech | Medium | → |
| Veterinary biotech & mRNA veterinary drugs | livestock-aqua | Medium | → |
| Veterinary genomics & companion-animal diagnostics | livestock-aqua | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.